Cardiovascular Disease

Midwest CEPAC

ICER will develop a report assessing the comparative clinical effectiveness and value of additive therapies for cardiovascular disease (CVD) for:

  • icosapent ethyl (Vascepa®, Amarin Pharma)
  • rivaroxaban (Xarelto®, Janssen Pharmaceuticals)

Date of review: September 2019 

For questions or additional information, please contact

Associated Meetings

September 26, 2019 10am - 4pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on additive CVD therapies.

Key Dates

Associated Materials